Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry

National Medical Journal of China

Volumn 85, Issue 45, 2005, Pages 3172-3175

  Pan, Yu Zhuo ^a   Xiao, Xue Yuan ^b   Zhao, Dan ^b   Zhang, Ling ^b   Ji, Guo Yi ^b   Li, Yang ^b   He, Da Cheng ^b   Zhao, Xue Jian ^b   Yang, Bao Xue ^b  

^a JILIN UNIVERSITY   (China)

^b NONE

Author keywords

Biomarker; Prostatic neoplasms; Protein chip

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ALGORITHM; ARTICLE; AUTOMATION; BIOINFORMATICS; CHINA; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; DECISION THEORY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SEROLOGY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

AGED; COMPUTATIONAL BIOLOGY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 31744433643     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003, 53:5-26.
2. Gu FL. Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J, 2003, 116:1391-1393.
3. Zhang L, Ji GY, Li XM, et al. The influence of Mass screening for prostate cancer on the status of the clinical prostate cancer. Chin J Urol, 2004, 25:103-105.
4. Zhang HF, Wang HL, Xu N et al. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen. Chin Med J, 2004, 117:67-70.
5. Kuwahara M, Tochigi T, Kawamura S et al. Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China. Urology, 2003, 61:137-141.
6. Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol, 2004, 172: 1297-1301.
7. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research, 2002, 62:3609-3614.
8. Zhang L, Ji GY, Li XM, et al. fPSA/tPSA ratio optimize the early diagnosis in the prostate cancer. Chin J Androl, 2004, 10: 582-585.
9. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 1987, 317:909-916.
10. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol, 1989, 141:1076-1083.
11. Xiao XY, He DC. Development of proteomic patterns for detecting lung cancer. Disease Markers, 2003, 19: 33-39.
12. Xiao XY, He DC. Discovery of laryngeal carcinoma by serum proteomic pattern analysis. Science in China, 2004, 47: 219-223.
13. Petricoin EF, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst, 2002, 94: 1576-1578.
14. Petricoin EF, Ornstein DK, Liotta LA. Clinical proteomics: Applications for prostate cancer biomarker discovery and detection. Urol Oncol, 2004, 22:322-328.
15. Petricoin EF, Ardekani A M, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359: 572-577.
16. Diamondis EP. Proteomic pattern in biological fluids: do they represent the future of cancer diagnosis? Clinical Chemistry, 2003, 49: 1272-1278.